The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,827,375 in first-year total cost, median $225,000.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OTC-H (10)]21
- Special Emphasis Panel[ZRG1 OTC-K (10)]3
Most frequent institutions
- AMBERGEN, INC2
- GIGAGEN, INC.2
- MIRIMUS, INC.2
- A'AS, INC.1
- ABREOS BIOSCIENCES, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2017 | Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research2R44CA188154-02 | PREMSRIRUT, PREM KHOVABUTR | MIRIMUS, INC., NY | $656,563 | ZRG1 |
| 2017 | Detection of Methylation and Translocation Events by Novel Sequencing Technology1R43CA214386-01 | CAO, HANLO, YU-HWAPEYTAVI, REGIS | BLUENOVO BIOSYSTEMS, INC., CA | $242,731 | ZRG1 |
| 2016 | Next-Generation Antibody Discovery and Development Technology2R44CA187852-02A1 | JOHNSON, DAVID SCOTT | GIGAGEN, INC., CA | $879,836 | ZRG1 |
| 2016 | Sensitive Single Cell PhosphoCount Platform for Drug-Insensitive Cell Detection and Combination Drug Screening for Leukemia1R43CA203681-01A1 | KING, JEFFREY SVU, TOTHU Q | VIROGENOMICS BIODEVELOPMENT, INC., OR | $299,931 | ZRG1 |
| 2016 | Automated Platform for Fixed Tissue Microdissection1R44CA199194-01A1 | KARSTEN, STANISLAV | NEUROINDX INC., CA | $265,643 | ZRG1 |
| 2016 | Development of an Assay Platform for Measuring Endogenous Kinase Activity1R43CA203671-01 | OUELLETTE, STEVEN BRADLEY | KINASENSE, LLC, IN | $243,120 | ZRG1 |
| 2016 | Photocleavage Technology for Improved Serum-based Multi-Biomarker Cancer Assays1R43CA203647-01A1 | LIM, MARK | AMBERGEN, INC, MA | $225,000 | ZRG1 |
| 2016 | Silk-Based Blood Sample Stabilization for Prostate Cancer Diagnostics1R43CA203675-01 | KLUGE, JONATHAN AUGUST | VAXESS TECHNOLOGIES, INC., MA | $223,416 | ZRG1 |
| 2016 | Development of Reagents for Sequencing Proteins and Protein Fragments on a Next-Generation DNA Sequencer1R43CA203629-01 | GUNDERSON, KEVIN L | ENCODIA, INC., CA | $211,400 | ZRG1 |
| 2015 | Profiling Circulating miRNA Without PCR for Early Detection of Pancreatic Cancer1R43CA199058-01 | ROY, SANTANUSARAF, RAVI | VAJRA INSTRUMENTS, INC., NE | $293,322 | ZRG1 |
| 2015 | Multiplexed DeNAno Protein Assay and Quantitation: Sequencing Based Proteomics1R43CA193128-01 | MESSMER, BRADLEY T | ABREOS BIOSCIENCES, INC., CA | $225,000 | ZRG1 |
| 2015 | Combined Optical and MR Microscopy System for Thin Tissue Histopathology Analysis1R43CA193134-01 | ACKERMAN, JEROME LNEVO, EREZ | ROBIN MEDICAL, INC., MD | $225,000 | ZRG1 |
| 2015 | NOVEL ULTRASENSITIVE CANCER BIOMARKER ASSAY PLATFORM UTILIZING PALLADIUM CATALYZED HIGH-GAIN CHEMICAL AMPLIFICATION1R43CA192674-01A1 | LELENTAL, MARK | CATASSAYS, NY | $225,000 | ZRG1 |
| 2015 | Sequenece-specific detection of proteases using electronic p-Chips in multiplex format1R43CA193087-01 | FUDALA, RAFALMANDECKI, WLODEK | PHARMASEQ, INC., NJ | $224,965 | ZRG1 |
| 2015 | KS-Detect: A solar-powered and smartphone integrated instrument for point-of-care diagnosis of Kaposi's sarcoma1R43CA193096-01 | JIANG, LI | A'AS, INC., PA | $224,835 | ZRG1 |
| 2015 | Hybridoma free multiplex approach for accelerating mouse monoclonal antibody generation1R43CA193101-01 | TRAN, HIEP T | ABZYME THERAPEUTICS, LLC, PA | $224,781 | ZRG1 |
| 2015 | Promote HPV screening rate with a non-invasive HPV POC cartridge1R43CA199211-01 | GAU, VINCENT JEN-JR | GENEFLUIDICS, INC., CA | $223,629 | ZRG1 |
| 2015 | In Situ RNA-FISH with Localized Profiling by Sequencing from FFPE1R43CA187787-01A1 | SELIGMANN, BRUCE E. | BIOSPYDER TECHNOLOGIES, INC., CA | $213,490 | ZRG1 |
| 2015 | Molecular characterization of circulating tumor cells with PCR-activated cell sorting1R43CA199152-01 | EASTBURN, DENNIS J | MISSION BIO, INC., CA | $199,892 | ZRG1 |
| 2015 | A Single Cell Multi-Protein Device to Facilitate Cancer Immunotherapy1R43CA199055-01 | MCCONNELL, TIMOTHY S | ISOPLEXIS, INC., DE | $181,989 | ZRG1 |
| 2015 | Rescuing Nucleic Acids from Formalin Damage in Cancer Specimens1R43CA199142-01 | ALIZADEH, ASH ARASHKOOL, ERIC T.ORBAI, LUCIAN | CELL DATA SCIENCES, INC., CA | $180,000 | ZRG1 |
| 2014 | Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays2R44CA161965-03 | LIM, MARK | AMBERGEN, INC, MA | $499,745 | ZRG1 |
| 2014 | B Cell Repertoire Molecular Platform for Antibody Drug Discovery1R43CA187852-01 | JOHNSON, DAVID SCOTT | GIGAGEN, INC., CA | $249,077 | ZRG1 |
| 2014 | RNA interference - genetically engineered mouse models(RNAi-GEMMs): a novel appro1R43CA188154-01 | FELLMANN, CHRISTOF | MIRIMUS, INC., NY | $189,010 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.